Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College

Articles

CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care

August 29th 2023

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Ongoing Clinical Trials in the Metastatic CRPC Setting

August 29th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

Potential for CDK4/6 Inhibitors in Metastatic CRPC

August 22nd 2023

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

Novel Therapeutic Targets in Metastatic CRPC

August 22nd 2023

A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.

Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy

August 15th 2023

Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.

Radioligands in the Treatment of Metastatic CRPC: Radium-223

August 15th 2023

Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.

Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617

August 8th 2023

Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials

August 8th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.

Advent of PARP Inhibitors in Metastatic CRPC

August 1st 2023

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer

August 1st 2023

Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.

Informing Systemic Therapy Selection With Negative Data in HSPC

July 25th 2023

A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.

What is the Role of Locoregional Therapy in Metastatic HSPC?

July 25th 2023

Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.

Systemic Treatment Armamentarium in Metastatic HSPC

June 26th 2023

Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.

Overview of Metastatic HSPC: Diagnosis and Risk Stratification

June 26th 2023

Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.

Efficacy of Sacituzumab Govitecan (SG) in Locally Advanced (LA) or Metastatic Urothelial Cancer (mUC) by Trophoblast Cell Surface Antigen 2 (Trop-2) Expression

June 14th 2023

Expert Scott Tagawa, MD, MS, FASCO, FACP, reviews recent clinical trial data on UGT1A1- and Trop-2–guided treatment of metastatic urothelial carcinoma.

Testing for PSMA in Community Settings

July 30th 2021

Scott T. Tagawa, MD, MS, FACP, discusses integration of prostate-specific membrane antigen [PSMA] positron emission tomography [PET] imaging into community practice to help identify potential candidates for PSMA-targeted radioligand therapy.

PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer

July 30th 2021

Scott T. Tagawa, MD, MS, FACP, reviews implications for treating prostate-specific membrane antigen (PSMA) -positive advanced prostate cancer with lutetium-177–PSMA-617 based on results of the phase III VISION study and additional trials in the pipeline.

The VISION Study in Metastatic CRPC

July 23rd 2021

An overview of safety and efficacy data presented at ASCO 2021 from the phase III VISION study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

PSMA PET Imaging in Advanced Prostate Cancer

July 23rd 2021

A discussion on the sensitivity and specificity of an emerging imaging modality, PSMA PET, in advanced prostate cancer.

PSMA as a Biomarker in Advanced Prostate Cancer

July 23rd 2021

Dr Scott T. Tagawa describes what prostate-specific membrane antigen (PSMA) is and explains its evolving role as a diagnostic, prognostic and therapeutic target in patients with advanced prostate cancer.